Genprex to Present at ARM Cell & Gene Therapy Investor Day in New York City

Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, today announced it will be presenting at the upcoming Cell & Gene Therapy Investor Day presented by the Alliance for Regenerative Medicine in New York City on March 21, 2019.

The one-day investor conference is unique in the medical and biotech communities as it focuses on fast-paced, concise presentations from more than 35 companies, fitting them all into a single-day conference while allowing incredible opportunities for one-on-one partnering with venture and strategic investors.

Genprex will present at the Seventh Annual ARM Cell & Gene Therapy Investor Day as follows:

Investor Presentation: Concurrent Tracks, Session 3

Date: Thursday, March 21, 2019

Time: 2:30-2:45 p.m. EST

Room: Main Bar Room

Venue: Metropolitan Club, One East 60th Street, New York, NY 10022

For the first time ever, Genprex – an Austin, Texas and Cambridge, Massachusetts-based biotech company committed to finding new ways to treat cancer – has been invited to present at the conference. Rodney Varner, Genprex’s Chairman and Chief Executive Officer, and Julien Pham, MD, MPH, Genprex’s President and Chief Operating Officer, will attend the conference on behalf of Genprex. Dr. Pham will lead the company’s presentation.

“I’m looking forward to attending Cell & Gene Therapy Investor Day for the first time, with the opportunity to share information about Genprex’s mission and our gene therapy technologies,” said Pham. “With a wide array of companies and industry leaders all presenting in a single day, this conference enables us and the investment community to take the pulse of where the industry is heading. It is an incredible honor to be a part of this event.”

Cell & Gene Therapy Investor Day, produced by the Alliance for Regenerative Medicine (ARM), an international community of companies, non-profit research institutions, patient organizations and other sector stakeholders dedicated to realizing the promise of regenerative medicine – is an annual conference designed to provide institutional, strategic and venture investors with unparalleled insight into financing opportunities for cell and gene therapy-based treatment and tools. Now in its seventh year, Cell & Gene Therapy Investor Day is a special, one-day conference that places an emphasis on brevity in corporate presentations, with more than 35 companies given 15 minutes each to showcase their work. More than 175 active investors and analysts will convene in New York City for the show, which will also feature fireside chats and expert-led panels, offering unprecedented levels of partnership opportunities and insight into present and future of regenerative medicine.

Investors and credentialed media members interested in attending the event should visit ARM’s website to contact the events team.

About Genprex, Inc.

Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. The Company’s lead product candidate, GPX-001 (quaratusugene ozeplasmid), is being evaluated as a treatment for non-small cell lung cancer (NSCLC). GPX-001 has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells. GPX-001 has also been shown to block mechanisms that create drug resistance. In January 2020, the U.S. Food and Drug Administration granted Fast Track Designation for GPX-001 for NSCLC in combination therapy with osimertinib (AstraZeneca’s Tagrisso®) for patients with EFGR mutations whose tumors progressed after treatment with osimertinib alone. For more information, please visit the Company’s web site at www.genprex.com or follow Genprex on Twitter, Facebook and LinkedIn.

About the Alliance for Regenerative Medicine
The Alliance for Regenerative Medicine (ARM) is the preeminent international organization focused specifically on the issues facing regenerative medicine and advanced therapies. It advocates for progress in gene therapy, cell therapy, and tissue engineering. Working with its members and policymakers, it fosters investment, research and development, and successful commercialization of safe, effective, and transformational therapies for patients around the world. In its seventh year, the ARM Cell & Gene Therapy Investor Day gives investors unmatched insight into the gene therapy industry. With significant technological advances and a number of recently approved products, the sector is poised for ever-increasing investor and analyst interest, and Cell & Gene Therapy Investor Day serves as the gateway for the investment world into the sector. The event includes clinical and commercial experts on-hand to address specific questions regarding the outlook for products from more than 35 companies, and how this sector is impacting key therapeutic areas including oncology, ophthalmology, rare disease, diabetes, cardiovascular disease, wound healing and tissue repair and neurodegenerative diseases. The program includes talks by key opinion leaders in the industry, analysts closely following the sector.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the effect of Genprex’s product candidates, alone and in combination with other therapies, on cancer and diabetes, regarding potential, current and planned clinical trials, regarding the Company’s future growth and financial status and regarding our commercial partnerships and intellectual property licenses. Risks that contribute to the uncertain nature of the forward-looking statements include the presence and level of the effect of our product candidates, alone and in combination with other therapies, on cancer; the timing and success of our clinical trials and planned clinical trials of GPX-001, alone and in combination with targeted therapies and/or immunotherapies, and whether our other potential product candidates, including GPX-002, our gene therapy in diabetes, advance into clinical trials; the success of our strategic partnerships, including those relating to manufacturing of our product candidates; the timing and success at all of obtaining FDA approval of GPX-001 and our other potential product candidates including whether we receive fast track or similar regulatory designations; costs associated with developing our product candidates and whether patents will ever be issued under patent applications that are the subject of our license agreements. These and other risks and uncertainties are described more fully under the caption “Risk Factors” and elsewhere in our filings and reports with the United States Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. We undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Media Contact
Genprex Media Relations
(877) 774-GNPX (4679) ext. #3
[email protected]